contact us
Bristol-Myers Squibb (NYSE:BMY) is granting Dr. Reddy's Laboratories (NYSE:RDY) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022.
Do Not Allow Advertisers to Use My Personal information
